<DOC>
	<DOC>NCT01971086</DOC>
	<brief_summary>Multi-centre, open-label, prospective, uncontrolled, single-arm, non-interventional study (NIS) with objective to collect and evaluate data concerning treatment with Rhinospray Plus in everyday curative routine treatment of acute rhinitis</brief_summary>
	<brief_title>Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary</brief_title>
	<detailed_description>Study Design: open, observational, single-arm, uncontrolled</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Tramazoline</mesh_term>
	<criteria>Inclusion criteria: 1. Patients who (or in case of 618 years old whose legal representative) have signed the Informed Consent 2. Male and female ambulatory outpatients being seen in a participating physicians office for routine care 3. Patients with a clinical diagnosis of Rhinitis acuta 4. Patient having the cognitive and functional abilities for answering the symptom specific questions 5. Patients having expressed the willingness to participate in this observational study 6. Patients at and above the age of 6 7. Rhinospray Plus naive patients (patients who have not used Rhinospray Plus before) Exclusion criteria: 1. Uncooperative patients based on physicians judgement 2. Patients with any conditions making the application of Rhinospray plus contraindicated 3. Patients currently enrolled in any clinical trial which requires a change in medication for their respiratory problems 4. Withdraw of Informed Consent 5. Pregnancy or breastfeeding as stated in the Summary of Product Characteristic (SmPC) 6. Patients with clinical diagnosis of allergic rhinitis</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>